Is AURA or BCRX more undervalued in 2026?

CirclFi compares Aura Biosciences, Inc. (AURA) and BioCryst Pharmaceuticals, Inc. (BCRX) using 13 institutional-grade valuation models. AURA has a Quality of Company score of 5.2/10 while BCRX scores 6.9/10.

Which is a better buy — AURA or BCRX?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do AURA and BCRX valuations compare?

AURA at $7.47 and BCRX at $8.91 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

AURA vs BCRX Valuation Comparison 2026 — Intrinsic Value Analysis

AURA

Biological Products, (No Diagnostic Substances)

Aura Biosciences, Inc.

Quality

5.2

out of 10

Value Trap

SAFE

Price

$7.47

Last close

Models

9/13

Active

BCRX

Biological Products, (No Diagnostic Substances)

BioCryst Pharmaceuticals, Inc.

Quality

6.9

out of 10

Value Trap

SAFE

Price

$8.91

Last close

Models

12/13

Active

Model-by-Model Comparison

Model	Type	AURA Fair Value	AURA Upside	BCRX Fair Value	BCRX Upside
Bayesian DCF	Intrinsic	$2.43	-67.4%	$14.22	+66.7%
Earnings Power Value	Intrinsic	—	—	$2.33	-74.2%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$0.59	-92.1%	$0.52	-94.2%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for AURA vs BCRX — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

AURA vs BCRX — Which Stock Is More Undervalued?

BCRX scores higher with a 6.9/10 quality rating vs AURA's 5.2/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Aura Biosciences, Inc. (AURA) and BioCryst Pharmaceuticals, Inc. (BCRX) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

AURA currently trades at $7.47 with a QOC of 5.2/10, while BCRX trades at $8.91 with a QOC of 6.9/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).